Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Prepaid Assets: 2021-2024

Historic Prepaid Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $6.9 million.

  • ARS Pharmaceuticals' Prepaid Assets rose 139.86% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 139.86%. This contributed to the annual value of $6.9 million for FY2024, which is 104.58% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Prepaid Assets stood at $6.9 million, which was up 104.58% from $3.4 million recorded in FY2023.
  • ARS Pharmaceuticals' Prepaid Assets' 5-year high stood at $6.9 million during FY2024, with a 5-year trough of $667,000 in FY2021.
  • In the last 3 years, ARS Pharmaceuticals' Prepaid Assets had a median value of $3.4 million in 2023 and averaged $4.5 million.
  • Data for ARS Pharmaceuticals' Prepaid Assets shows a peak YoY soared of 397.60% (in 2022) over the last 5 years.
  • ARS Pharmaceuticals' Prepaid Assets (Yearly) stood at $667,000 in 2021, then soared by 397.60% to $3.3 million in 2022, then rose by 1.42% to $3.4 million in 2023, then soared by 104.58% to $6.9 million in 2024.